Presentation TVT 2022 Deep Dive Into Imaging Requirements for Orthotopic and Heterotopic Tricuspid Valve Replacements Presenter: Edwin Ho June 08, 2022
Presentation TVT 2022 Frequency, Mechanisms, and Current Management Presenter: Nir Uriel June 08, 2022
Presentation TVT 2022 Rapidly Evolving EU Experiences With the JenaValve for AR and AS Presenter: Matti Adam June 08, 2022
Presentation TVT 2022 Role of the RV in Device Choice: Which Right Ventricle Is Right for You? Presenter: Omar Khalique June 08, 2022
Presentation TVT 2022 Updates on the Dedicated JenaValve TAVR System and the ALIGN AR Trial Presenter: Vinod Thourani June 08, 2022
Presentation TVT 2022 Case 2: Case With Large Annulus, Reduced RV, and Cardiac Cirrhosis Presenter: Diarmaid S. Hughes June 08, 2022
Presentation TVT 2022 Case 1: Case With Replacement as a Choice (Large Gap, Torrential TR) Presenter: Diarmaid S. Hughes June 08, 2022
Presentation TVT 2022 Current Transcatheter Landscape: Importance of Tricuspid Valve Imaging in Emerging Transcatheter Therapies Presenter: Fabien Praz June 08, 2022
Presentation TVT 2022 "Looks Do Matter": Anatomical Considerations for Determining Device Choice Presenter: Rhonda Miyasaka June 08, 2022
Presentation TVT 2022 IVUS-Guided Doppio BASILICA, Valve-in-Valve, and Bioprosthetic Valve Fracture for Degenerated 19 mm Magna Ease Presenter: Pier Pasquale Leone June 08, 2022
Presentation TVT 2022 Synchronous Type 3 EVAR Endoleaks Following Transfemoral Transcatheter Aortic Valve Replacement Presenter: Sankalp Patel June 08, 2022
Presentation TVT 2022 Approach to TAVR in Setting of a Complicated Left Atrial Thrombus in Transit Presenter: Rimmy Garg June 08, 2022
Presentation TVT 2022 Balloon Expandable TAVR for Severe Aortic Insufficiency: Device Anchoring by Pre-existent Mitral Annuloplasty Ring Presenter: Yashasvi Chugh June 08, 2022
Presentation TVT 2022 Sinus Sequestration After TAVR With Coronary Protection: Diagnosis and Management Presenter: Andrea Scotti June 08, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022